The financing package is structured to bypass the typical equity dilution associated with growth funding, allowing Amprion to retain full management control and governance. CEO Russ Lebovitz noted that the capital arrives as clinical and research demand for reliable diagnostic markers continues to climb worldwide. By leveraging this non-dilutive funding, the company aims to accelerate the adoption of its SAAmplify-aSYN assay, currently the only seed amplification test available for synucleinopathies.

Matt Hoffman, Managing Director at Decathlon Capital Partners, pointed to the urgent need for earlier and more precise neurological diagnostics as the primary driver for the partnership. Beyond clinical applications, Amprion continues to utilize its intellectual property to support biopharma partners in identifying new drug candidates. This injection of resources allows the company to scale its testing platform while maintaining the operational flexibility required to navigate the competitive landscape of precision medicine.